University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Amit J. Sabnis, MD

Amit J. Sabnis, MD

Assistant Professor, Pediatric Hematology-Oncology, UCSF Benioff Children’s Hospital San Francisco

Cancer Center Program Memberships

Pediatric Malignancies


Stanford University, Stanford CA, BS, 06/2003, Biological Sciences
Stanford University, Stanford CA, MS, 06/2003, Biological Sciences
Univ. of California San Francisco, MD, 05/2008, Medicine
Univ. of California San Francisco, Resident, 06/2011, Pediatrics
Univ. of California San Francisco, Fellow, 06/2014, Pediatric Hematology-Oncology

Professional Experience

  • 2011-2014
    Fellow, Pediatric Hematology-Oncology, UCSF Benioff Children’s Hospital San Francisco
  • 2014-2015
    Clinical Instructor, Pediatric Hematology-Oncology, UCSF Benioff Children’s Hospital San Francisco
  • 2015-present
    Adjunct Assistant Professor, Pediatric Hematology-Oncology, UCSF Benioff Children’s Hospital San Francisco 

Honors & Awards

  • 2007
    American Society of Hematology Travel/Merit Award
  • 2007-2008
    UCSF Certificate of Graduate Curriculum in Biomedical Research
  • 2008
    Inducted into Alpha Omega Alpha Honor Society
  • 2009
    UCSF Pediatrics Resident Teaching Award
  • 2011
    Lucy S. Crain Award for providing exceptional primary care to patients with special needs
  • 2012
    Accepted into AACR “Molecular Biology in Clinical Oncology” workshop
  • 2013
    Campini Foundation Fellowship in Pediatric Oncology Research
  • 2017
    2017 AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research
  • 2017
    Caroline Casey Award for Dignity and Worth of Persons

Selected Publications

  1. Giles Robinson, Ami Desai, Karen Gauvain, Ellen Basu, Kathleen Dorris, Luke Maese, Amit Sabnis, Jennifer Foster, Suzanne Shusterman, Janet Yoon, Brian Weiss, Mohamed Abdelbaki, Mufiza Farid-Kapadia, Georgina Meneses-Lorente, Alison Cardenas, Katherine Hutchinson, Guillaume Bergthold, Edna Chow Maneval, Elizabeth Fox, Amar Gajjar. PDCT-13. ENTRECTINIB IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS. Neuro-Oncology. 2019 Nov 11; 21(Supplement_6):vi186-vi186.
    View on PubMed
  2. Heunis JC, Cheah JW, Sabnis AJ, Wustrack RL. Use of three-dimensional printing and intraoperative navigation in the surgical resection of metastatic acetabular osteosarcoma. BMJ Case Rep. 2019 Sep 30; 12(9).
    View on PubMed
  3. Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, Flanagan J, Chan E, Asthana S, Ideker T, Wu W, Suzuki J, Barad BA, Kirichok Y, Fraser JS, Weiss WA, Krogan NJ, Tulpule A, Sabnis AJ, Bivona TG. Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers. Cell Rep. 2019 Aug 27; 28(9):2317-2330.e8.
    View on PubMed
  4. Giles W. Robinson, Amar J. Gajjar, Karen Marie Gauvain, Ellen M. Basu, Margaret E Macy, Luke Devon Maese, Amit J. Sabnis, Jennifer Haunani Foster, Suzanne Shusterman, Janet Yoon, Brian D. Weiss, Mohamed Abdelbaki, Mufiza Farid-Kapadia, Georgina Meneses-Lorente, Alison Cardenas, Katherine Hutchinson, Guillaume Bergthold, Edna Chow Maneval, Elizabeth Fox, Ami Vijay Desai. Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors. Journal of Clinical Oncology. 2019 May 20; 37(15_suppl):10009-10009.
    View on PubMed
  5. Sabnis AJ, Bivona TG. Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends Mol Med. 2019 03; 25(3):185-197.
    View on PubMed
  6. Sannino S, Guerriero CJ, Sabnis AJ, Stolz DB, Wallace CT, Wipf P, Watkins SC, Bivona TG, Brodsky JL. Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci. 2018 09 05; 131(17).
    View on PubMed
  7. Ami Vijay Desai, Garrett M. Brodeur, Jennifer Foster, Stacey L. Berg, Ellen M. Basu, Suzanne Shusterman, Amit J. Sabnis, Margaret Macy, Janet Yoon, Karen Gauvain, Vanessa Esquibel, Edna Chow Maneval, Pratik S. Multani, Elizabeth Fox. Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors. Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):10536-10536.
    View on PubMed
  8. Cohen JN, Sabnis AJ, Krings G, Cho SJ, Horvai AE, Davis JL. EWSR1-NFATC2 gene fusion in a soft tissue tumor with epithelioid round cell morphology and abundant stroma: a case report and review of the literature. Hum Pathol. 2018 11; 81:281-290.
    View on PubMed
  9. Wattier RL, Levy ER, Sabnis AJ, Dvorak CC, Auerbach AD. Reducing Second Gram-Negative Antibiotic Therapy on Pediatric Oncology and Hematopoietic Stem Cell Transplantation Services. Infect Control Hosp Epidemiol. 2017 09; 38(9):1039-1047.
    View on PubMed
  10. Sabnis AJ, Bivona TG. HSP70 dependence in rhabdomyosarcoma: Seed or soil? Cell Cycle. 2017 01 17; 16(2):147-148.
    View on PubMed
  11. Sabnis AJ, Guerriero CJ, Olivas V, Sayana A, Shue J, Flanagan J, Asthana S, Paton AW, Paton JC, Gestwicki JE, Walter P, Weissman JS, Wipf P, Brodsky JL, Bivona TG. Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma. Proc Natl Acad Sci U S A. 2016 08 09; 113(32):9015-20.
    View on PubMed
  12. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47.
    View on PubMed
  13. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona TG. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6.
    View on PubMed
  14. Amit Sabnis, Jonathan L. Finlay, Sabine Mueller. Neurologic Emergencies. Supportive Care in Pediatric Oncology. 2015 Jan 1; 71-96.
    View on PubMed
  15. Molina-Vila MA, Nabau-Moretó N, Tornador C, Sabnis AJ, Rosell R, Estivill X, Bivona TG, Marino-Buslje C. Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues. Hum Mutat. 2014 Mar; 35(3):318-28.
    View on PubMed
  16. Sabnis AJ, Bivona TG. FGFR fusions in the driver's seat. Cancer Discov. 2013 Jun; 3(6):607-9.
    View on PubMed
  17. Santaguida M, Schepers K, King B, Sabnis AJ, Forsberg EC, Attema JL, Braun BS, Passegué E. JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell. 2009 Apr 07; 15(4):341-52.
    View on PubMed
  18. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol. 2009 Mar 17; 7(3):e59.
    View on PubMed
  19. McGowan KA, Li JZ, Park CY, Beaudry V, Tabor HK, Sabnis AJ, Zhang W, Fuchs H, de Angelis MH, Myers RM, Attardi LD, Barsh GS. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet. 2008 Aug; 40(8):963-70.
    View on PubMed

Go to UCSF Profiles, powered by CTSI